N-2-(4-t-butylphenyl)butyl Trifluoromethanesulfonamide | 211311-59-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: N-2-(4-t-butylphenyl)butyl Trifluoromethanesulfonamide
• 英文别名: N-[2-(4-tert-butylphenyl)butyl]-1,1,1-trifluoromethanesulfonamide
• CAS: 211311-59-0
• 化学式: C₁₅H₂₂F₃NO₂S
• 分子量: 337.406
• InChiKey: HBNHMUQCLCASNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• (BIS)sulfonamide derivatives
  申请人：——

  公开号：US20040054009A1

  公开（公告）日：2004-03-18

  The present invention provides (bis) sulfonamide derivatives of formula (I) useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.

  本发明提供了公式(I)的(双)磺胺衍生物，可用于增强哺乳动物的谷氨酸受体功能，因此可用于治疗多种疾病，如精神疾病和神经系统疾病。
• [EN] SULPHONAMIDE DERIVATIVES<br/>[FR] DERIVES SULFAMIDES
  申请人：ELI LILLY AND COMPANY

  公开号：WO1998033496A1

  公开（公告）日：1998-08-06

  (EN) Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula (I): R1-L-NHSO2R2, in which R1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring; and pharmaceutically acceptable salts thereof. Also disclosed are novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them.(FR) La présente invention concerne la fonction du récepteur du glutamate chez un mammifère qui peut être potentialisée par l'utilisation d'une quantité effective d'un composé représenté par la formule (I): R1-L-NHSO2R2 dans laquelle R1 représente un groupe hétéroaromatique ou aromatique substitué ou non substitué; R2 représente (1-6C) alkyle, (3-6C) cycloalkyle, (1-6C) fluoroalkyle, (1-6C) chloroalkyle, (2-6C) alkényle, (1-4C) alkoxy (1-4C) alkyle, phényle substitué ou non substitué par halogène, (1-4C) alkyle ou (1-4C) alkoxy, ou un groupe de formule R3R4N dans lequel R3 et R4 représentent individuellement(1-4C) alkyle ou forment conjointement avec l'atome d'azote auquel ils sont liés un groupe azétidinyle, pyrrolidinyle, pipéridinyle, morpholino, pipérazinyle, hexahydroazépinyle, ou un groupe octahydroazocinyle; et L représente une chaîne (2-4C) alkylène substituée ou non substituée par un ou deux substituants individuellement sélectionnés parmi (1-6C) alkyle, aryle (1-6C) alkyle, (2-6C) alkényle, aryle (2-6C) alkényle et aryle, ou par deux substituants lesquels forment conjointement, avec le ou les atomes de carbone auxquels ils sont liés, un noyau (3-8C) carbocyclique. L'invention décrit également les sels pharmaceutiquement acceptables du composé de la formule (I), de nouveaux composés représentés par la formule (I), les procédés de leur préparation ainsi que les compositions pharmaceutiques les renfermant.

  该文描述了一种化合物（I）的公式，其中R1代表未取代或取代的芳香或杂芳基团；R2代表（1-6C）烷基，（3-6C）环烷基，（1-6C）氟代烷基，（1-6C）氯代烷基，（2-6C）烯基，（1-4C）烷氧（1-4C）烷基，未取代或取代的苯基，该苯基被卤素，（1-4C）烷基或（1-4C）烷氧基取代，或者一个公式R3R4N的基团，其中R3和R4各自独立地表示（1-4C）烷基，或者与它们所连接的氮原子一起形成一个氮杂环基团，如氮杂丙环基团，吡咯烷基团，哌啶基团，吗啉基团，哌嗪基团，六氢氮杂环己基团或八氢氮杂环辛基团；L代表一个（2-4C）烷基链，该链未取代或取代，取代基独立地选自（1-6C）烷基，芳基（1-6C）烷基，（2-6C）烯基，芳基（2-6C）烯基和芳基，或者由两个取代基组成，这两个取代基与它们所连接的碳原子或碳原子一起形成一个（3-8C）碳环；以及其药学上可接受的盐。同时还公开了公式（I）的新化合物，制备它们的方法以及含有它们的药物组合物。该文探讨了在哺乳动物中谷氨酸受体功能的增强。
• Sulphonamide derivatives
  申请人：——

  公开号：US20020002158A1

  公开（公告）日：2002-01-03

  Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula R 1 —L—NHSO 2 R 2 I in which R 1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R 2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R 3 R 4 N in which R 3 and R 4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring; and pharmaceutically acceptable salts thereof. Also disclosed are novel compounds of formula I, processes for preparing them and pharmaceutical compositions containing them.

  一种具有公式R1-L-NHSO2R2的化合物的有效量可以增强哺乳动物中的谷氨酸受体功能，其中R1表示未取代或取代的芳香或杂环芳香基团；R2表示（1-6C）烷基，（3-6C）环烷基，（1-6C）氟烷基，（1-6C）氯烷基，（2-6C）烯基，（1-4C）烷氧基（1-4C）烷基，苯基，该苯基未取代或通过卤素，（1-4C）烷基或（1-4C）烷氧基取代，或公式R3R4N的基团，其中R3和R4各自独立地表示（1-4C）烷基，或者与它们所连接的氮原子一起形成一个氮杂环基团，包括氮杂丙环基团，吡咯环基团，哌啶环基团，吗啉环基团，哌嗪环基团，六氢氮杂环基团或八氢氮杂环基团；L表示未取代或通过（1-6C）烷基，芳基（1-6C）烷基，（2-6C）烯基，芳基（2-6C）烯基和芳基中选择的一种或两种独立选择的取代基取代的（2-4C）烷基链，或者通过两种取代基与它们所连接的碳原子或碳原子一起形成一个（3-8C）碳环；以及其药学上可接受的盐。还公开了公式I的新化合物，制备它们的过程以及包含它们的制药组合物。
• SULPHONAMIDE DERIVATIVES
  申请人：Arnold B. Macklin

  公开号：US20060030599A1

  公开（公告）日：2006-02-09

  Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula R 1 -L-NHSO 2 R 2 I in which R 1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R 2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C) chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R 3 R 4 N in which R 3 and R 4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring; and pharmaceutically acceptable salts thereof. Also disclosed are novel compounds of formula I, processes for preparing them and pharmaceutical compositions containing them.

  一种化合物可以增强哺乳动物中谷氨酸受体的功能，该化合物的化学式为R1-L-NHSO2R2，其中R1表示未取代或取代的芳香或杂芳基团；R2表示(1-6C)烷基，(3-6C)环烷基，(1-6C)氟代烷基，(1-6C)氯代烷基，(2-6C)烯基，(1-4C)烷氧基(1-4C)烷基，苯基，未取代或取代的卤素、(1-4C)烷基或(1-4C)烷氧基，或者公式R3R4N的基团，其中R3和R4各自独立地表示(1-4C)烷基，或者与它们连接的氮原子一起形成氮杂环丙烷基、吡咯烷基、哌啶基、吗啉基、哌嗪基、六氢氮杂环庚烷基或八氢氮杂环二十烷基；L表示未取代或取代的(2-4C)烷基链，该链通过一个或两个独立选择的取代基未取代或取代，这些取代基是(1-6C)烷基，芳基(1-6C)烷基，(2-6C)烯基芳基(2-6C)烯基芳基，或者通过两个取代基与它们连接的碳原子或碳原子形成(3-8C)环状碳基环；以及其药学上可接受的盐。还公开了公式I的新化合物，制备它们的方法以及含有它们的制药组合物。
• Sulphonamide Derivatives
  申请人：Eli Lilly & Company

  公开号：EP1528055A2

  公开（公告）日：2005-05-04

  The present invention provides compounds of the formula: wherein R14 represents a phenyl group which is unsubstituted or substituted by one or two of halogen; nitro; cyano; (1-10C) alkyl; (2-10C)alkenyl; (2-10C)alkynyl; (3-8C)cycloalkyl; halo(1-10C)alkyl; (CH2)zX3R15 in which z is 0 or an integer of from 1 to 4, X3 represents O, S, NR16, CO, COO, OCO, CONR17, NR18CO, OCONR19, R15 represents hydrogen, (1-10C) alkyl, (3-10C)alkenyl, (3-10C)alkynyl or (3-8C)-cycloalkyl and R16, R17, R18 and R19 each independently represents hydrogen or (1-10C)alkyl, or R15 and R16, R17, R18 or R19 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino group; or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions comprising these compounds.

  本发明提供了式中化合物： 其中 R14 代表未被取代或被卤素、硝基、氰基、(1-10C)烷基、(2-10C)烯基、(2-10C)炔基、(3-8C)环烷基、卤代(1-10C)烷基中的一个或两个取代的苯基；(CH2)zX3R15 其中 z 是 0 或 1 至 4 的整数，X3 代表 O、S、NR16、CO、COO、OCO、CONR17、NR18CO、OCONR19，R15 代表氢、(1-10C)烷基、(3-10C)烯基、(3-10C)炔基或(3-8C)环烷基，R16、R17、R18和R19各自独立地代表氢或(1-10C)烷基，或R15和R16、R17、R18或R19与它们所连接的氮原子一起形成氮杂环丁基、吡咯烷基、哌啶基或吗啉基；或其药学上可接受的盐。还公开了包含这些化合物的药物组合物。